Home
Name
KRd
Alternate names
None
Primary Site
None
Histology
Multiple myeloma
Radiation
None
Remarks
July 2020 KRd - carfilzomib (Kyprolis) -- chemotherapy, lenalidomide (Revlimid) -- BRM, and dexamethasone -- hormone is a new treatment for newly treated patients with standard- and intermediate-risk multiple myeloma who are not slated for immediate autologous stem cell transplantation (ASCT).
IMPORTANT NOTE: Code both chemotherapy and BRM in the treatment fields. Dexamethasone is an ancillary drug and is not coded.
IMPORTANT NOTE: Code both chemotherapy and BRM in the treatment fields. Dexamethasone is an ancillary drug and is not coded.
Drugs for KRd
Name
Alternate Names
Kyprolis
Abbreviations
None
Category
Chemotherapy
Subcategory
Proteasome inhibitor
NSC Number
None
Primary Site
Multiple myeloma
Histology
None
Remarks
September 4, 2020: FDA has approved Kyprolis (carfilzomib) and Darzalex (daratumumab) in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.
July 20, 2012 the FDA approved Kyprolis under the accelerated approval program for the treatment of multiple myeloma.
July 20, 2012 the FDA approved Kyprolis under the accelerated approval program for the treatment of multiple myeloma.
Coding
This drug should be coded
Name
Alternate Names
Revlimid
lenalidomide
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
Cytostatic agent--antiangiogenesis agent
NSC Number
703813
Primary Site
5q- MDS
CLL
MDS
Multiple myeloma
melanoma
Lymphoma
Histology
None
Remarks
May 28, 2019: FDA approved lenalidomide (REVLIMID) in combination with a rituximab product for previously treated follicular lymphoma (FL) and previously treated marginal zone lymphoma (MZL).
2/22/2017: FDA approved lenalidomide (Revlimid) as maintenance therapy for patients with multiple myeloma following autologous stem cell transplant.
July 2013 UPDATE: Revlimid received FDA approval for use in the treatment of mantle cell lymphoma (MCL) whose disease has relapsed after two prior therapies, one of which included bortezomib.
FDA approved for MDS 2005, for multiple myeloma 2006, orphan drug status CLL
Thalidomide analog immunomodulatory derivative.
February 20, 2015 update: FDA approved revlimid given in combination with dexamethasone as first course treatment for newly diagnosed multiple myeloma.
2/22/2017: FDA approved lenalidomide (Revlimid) as maintenance therapy for patients with multiple myeloma following autologous stem cell transplant.
July 2013 UPDATE: Revlimid received FDA approval for use in the treatment of mantle cell lymphoma (MCL) whose disease has relapsed after two prior therapies, one of which included bortezomib.
FDA approved for MDS 2005, for multiple myeloma 2006, orphan drug status CLL
Thalidomide analog immunomodulatory derivative.
February 20, 2015 update: FDA approved revlimid given in combination with dexamethasone as first course treatment for newly diagnosed multiple myeloma.
Coding
This drug should be coded
